With: Isis Pharmaceuticals
What: $1.9B partnership
Summary: Genzyme forked out a hefty $1.9 billion to partner with Isis Pharmaceuticals on development of promising cardiovascular drug mipomersen. Isis got $375 million up front. Genzyme reportedly outbid 10 other companies for rights to the drug, which blocks a gene that opens the gate to cholesterol in the blood. The drug is now in multiple Phase III trials.